SINFH accounts for approximately 25 to 50 percent of all osteonecrosis of the femoral head cases, making it one of the most significant complications of long-term glucocorticoid therapy. The condition arises when abnormal bone metabolism, lipid metabolism imbalance, and blood microcirculation disorders in the femoral head lead to trabecular fracture, bone tissue necrosis and collapse, and ultimately hip dysfunction. Despite decades of research, the exact pathogenesis has remained unclear, with bone metabolism disorders, vascular endothelial injury, cell apoptosis, inflammation, and lipid metabolism disturbances considered the main pathological manifestations.

The review’s central conceptual contribution is the distinction between physiological and pathological roles of ROS, which the authors frame as an “oxidative window”—the optimal range of ROS required for normal cellular processes. At low to moderate concentrations, ROS function as essential second messengers generated primarily by NADPH oxidases (NOX enzymes) in response to growth factors and cytokines, regulating cell proliferation, survival, differentiation, migration, and metabolism. For example, BMP-2 activates NOX to induce physiological ROS production that serves as a signaling trigger for osteoblast differentiation, while ROS-mediated activation of ERK1/2 and p38 MAPK pathways is crucial for osteoblast proliferation. In contrast, supraphysiological ROS levels overwhelm cellular antioxidant defenses, causing mitochondrial DNA mutations, lipid peroxidation, protein carbonylation, and irreversible cell damage that triggers bone metabolism disorders, vascular endothelial injury, and apoptosis.

The transition from physiological signaling to pathological oxidative stress depends on the magnitude, duration, and subcellular location of ROS production. This concentration-dependent duality has profound therapeutic implications: the goal in SINFH should not be complete elimination of ROS, but rather restoration of redox homeostasis within the oxidative window. The authors support this with evidence that the antioxidant N-acetylcysteine inhibits mineralization of osteoblast-like MC3T3-E1 cells in a dose-dependent manner, suggesting that physiological levels of ROS are actually required for osteoblast mineralization.

On the bone formation side, the review highlights the complex and sometimes opposing roles of sirtuin family members in regulating oxidative stress and osteogenic differentiation. SIRT6 and SIRT3 function as protective factors: SIRT6 knockout mice showed decreased alkaline phosphatase expression and reduced osteogenic differentiation of bone marrow mesenchymal stem cells (BMSCs), while promoting SIRT6 expression reduced ROS accumulation and enhanced osteogenic activity. Resveratrol activates the AMPK/PGC-1α/SIRT3 pathway, inhibiting oxidative stress in BMSCs and enhancing Runx2 and osteocalcin expression. In contrast, SIRT2 exerts opposing effects—it induces oxidative stress and promotes BMSC apoptosis, and inhibiting SIRT2 expression alleviates both, slowing SINFH progression. This functional divergence suggests that therapeutic strategies should selectively target specific sirtuin isoforms rather than broadly modulating sirtuin activity.

On the bone resorption side, the review details how oxidative stress drives hyperactive osteoclasts. In necrotic areas of the human femoral head, antioxidant enzymes including catalase, γ-glutamylcysteine synthetase, and superoxide dismutase 1 are significantly downregulated, while osteoclast-related proteins such as cathepsin K and tartrate-resistant acid phosphatase are significantly upregulated. Under oxidative stress conditions, ROS leads to overactivation of RANKL and its receptor RANK, triggering the MAPKs signaling cascade and activating NFATC1, which increases osteoclast differentiation and enhances bone resorption. The Nrf2 transcription factor emerges as a key regulator that can inhibit excessive bone resorption caused by oxidative stress by modulating RANKL-RANK binding, with compounds like Tanshinone I from Danshen shown to increase antioxidant enzyme activity through Nrf2 activation.

The review also examines how oxidative stress accelerates apoptosis of bone cells through the Bcl-2/BAX pathway, with glucocorticoid-induced ROS increasing endoplasmic reticulum stress and mitochondrial DNA damage. Markers of DNA oxidative damage such as 8-hydroxy-2′-deoxyguanosine (8-OHdG) are positively correlated with bone cell apoptosis in SINFH patients, and antioxidants like diphenyleneiodonium and N-acetylcysteine can reduce 8-OHdG levels and reverse dexamethasone-mediated bone cell apoptosis. Vitamin E has been shown to reduce caspase-3 expression while upregulating Bcl-2, alleviating DNA oxidative damage in bone marrow hematopoietic cells.

Vascular injury represents another critical axis. Oxidative stress causes structural and functional impairments of vascular endothelial cells, increases the risk of thrombosis, and exacerbates ischemia and hypoxia in the femoral head. Li and colleagues found that two weeks after steroid injection, the perfusion frequency of small vessels in the femoral head of rats was significantly reduced, with extensive oxidative damage in bone marrow vessels; the antioxidant edaravone significantly reduced this damage and increased small vessel perfusion. Thymoquinone has been shown to reduce malondialdehyde levels and increase glutathione levels, alleviating oxidative stress-induced vascular endothelial injury, while hydrogen-rich saline increased GSH levels and microvascular density in an experimental rabbit model.

Perhaps the most novel aspect of the review is its treatment of the bidirectional relationship between lipid metabolism disturbances and oxidative stress. Glucocorticoids profoundly affect lipid metabolism by promoting adipogenic differentiation of BMSCs at the expense of osteogenic differentiation, resulting in intraosseous lipid accumulation, adipocyte hypertrophy, and increased marrow fat content that mechanically compresses sinusoids and impairs microcirculation. The accumulated lipids serve as substrates for lipid peroxidation, generating malondialdehyde and 4-hydroxynonenal—products that are not merely passive markers but active mediators that form covalent adducts with proteins, induce mitochondrial dysfunction promoting further ROS production, and activate inflammatory signaling pathways. Conversely, lipid accumulation in bone marrow adipocytes and osteoblasts induces endoplasmic reticulum stress and mitochondrial dysfunction, both potent sources of ROS, while oxidized low-density lipoproteins accumulated in bone tissue can activate NOX enzymes, amplifying ROS production. This creates a vicious cycle: glucocorticoid-induced lipid accumulation triggers oxidative stress, which promotes lipid peroxidation, which exacerbates oxidative damage and inflammation, leading to further tissue injury.

The review also maps the crosstalk among oxidative stress-mediated pathological processes, identifying self-amplifying loops that connect vascular injury, inflammation, apoptosis, and lipid metabolism. Vascular injury induced by oxidative stress leads to ischemia and hypoxia, which in turn exacerbates oxidative stress through mitochondrial electron transport chain dysfunction during reoxygenation, hypoxia-inducible factor-mediated NOX expression, and depletion of cellular antioxidant reserves. ROS activates NF-κB, a master transcription factor for pro-inflammatory cytokines including TNF-α, IL-1β, and IL-17, which not only promote osteoclast activation but also stimulate further ROS production from macrophages and other immune cells. Apoptotic cells release damage-associated molecular patterns that activate inflammatory responses and promote osteoclast differentiation, creating a situation where bone resorption exceeds formation and accelerating structural deterioration.

On the signaling pathway front, the review comparatively evaluates the Nrf2/Keap1, Wnt/β-catenin, Akt, and JNK/c-Jun pathways for their relative importance and therapeutic potential. The Nrf2/Keap1 pathway emerges as most promising for intervention due to its central role as the master regulator of the antioxidant response, the availability of pharmacological activators with established safety profiles, and its integration with other pathways. The Akt pathway ranks second given its unique position simultaneously regulating osteogenesis via Runx2, angiogenesis via HIF-1α/VEGF, apoptosis via Bad/Bcl-2, and oxidative stress via Nrf2/HO-1. Astragaloside IV, an extract from Astragalus, has been shown to inhibit cell apoptosis and oxidative stress through the Akt/Bad/Bcl-2 and Akt/Nrf2/HO-1 pathways, preventing glucocorticoid-induced SINFH. The JNK/c-Jun pathway, though clearly involved in oxidative stress-induced apoptosis, presents challenges for therapeutic targeting due to its context-dependent effects.

Despite promising preclinical results, the clinical translation of antioxidant therapy for SINFH faces multiple bottlenecks. Many potent antioxidants such as resveratrol and curcumin exhibit poor oral bioavailability and undergo rapid metabolism, limiting their therapeutic efficacy. Achieving therapeutic concentrations specifically within the femoral head remains challenging due to the site’s limited vascular access, though local delivery systems including hydrogels, 3D-printed scaffolds, and nanoparticles offer potential solutions requiring optimization. The optimal timing of antioxidant intervention—whether before, during, or after glucocorticoid administration—remains undefined, as pre-treatment might prevent initial oxidative damage but could interfere with the glucocorticoid’s therapeutic effects, while post-treatment might arrive too late after irreversible damage has occurred. Current clinical markers of oxidative stress, including malondialdehyde, superoxide dismutase, and glutathione, suffer from poor specificity influenced by diet and circadian rhythm, lack of tissue specificity, and diurnal variation, though emerging biomarkers such as oxidized LDL, F2-isoprostanes, and protein carbonyls offer improved specificity pending validation in SINFH cohorts.

Given the multifactorial nature of SINFH pathogenesis, the authors argue that antioxidant monotherapy may be insufficient, and rational combination strategies targeting multiple pathological nodes simultaneously warrant investigation. These include combining antioxidants with angiogenic factors to address both oxidative damage and vascular insufficiency, with anti-inflammatory agents to break the inflammation-ROS cycle, with bone anabolic drugs to promote bone formation while protecting against oxidative damage, and with lipid-lowering agents possessing antioxidant properties to target the lipid metabolism-oxidative stress axis. The review ultimately concludes that maintaining a dynamic balance between oxidation and antioxidation may be more important than completely suppressing redox reactions, positioning oxidative stress regulation as a promising new direction for the prevention and treatment of this increasingly recognized complication of steroid therapy.

Subject of Research: Oxidative stress mechanisms in steroid-induced necrosis of the femoral head

Article Title: Oxidative stress in steroid-induced necrosis of femoral head: a review revealing new insights into pathogenic mechanisms

Article References: Wu, Y., Ma, R., & Jiang, H. (2026). Oxidative stress in steroid-induced necrosis of femoral head: a review revealing new insights into pathogenic mechanisms. Frontiers in Musculoskeletal Disorders, 4, Article 1788598. https://doi.org/10.3389/fmscd.2026.1788598

Image Credits: AI Generated

DOI: 10.3389/fmscd.2026.1788598

Keywords: oxidative stress, steroid-induced necrosis of femoral head, reactive oxygen species, antioxidants, Nrf2 signaling, osteonecrosis, glucocorticoids, bone metabolism, apoptosis, vascular injury, lipid metabolism, inflammation

Osteoporosis is a systemic metabolic disease in which the delicate balance between bone-building cells called osteoblasts and bone-resorbing cells called osteoclasts tips decisively toward loss. The result is porous, fragile bone that fractures under trivial loads, and the human toll is enormous: hip fractures alone are associated with significant mortality within the first year, and the disease affects hundreds of millions of people worldwide, with prevalence rising steeply as populations age. Current pharmacological options, including bisphosphonates, denosumab, and parathyroid hormone analogues, can slow bone loss or stimulate bone formation, but each comes with limitations ranging from gastrointestinal irritation to rare but serious adverse effects such as osteonecrosis of the jaw. This therapeutic gap has fueled intense interest in natural compounds that might modulate bone metabolism with fewer side effects, and quercetin has long been a tantalizing candidate in that search.

Quercetin belongs to the flavonol subclass of flavonoids, a family of polyphenolic compounds that plants synthesize in response to environmental stress. Chemically, its structure is built around a three-ringed backbone decorated with five hydroxyl groups, a configuration that makes it a remarkably potent scavenger of reactive oxygen species. That antioxidant capacity is central to why bone researchers became interested in it in the first place. Oxidative stress is now recognized as a key driver of osteoporosis, particularly in the context of estrogen deficiency: reactive oxygen species push bone marrow mesenchymal stem cells away from the osteogenic lineage and toward adipogenic differentiation, meaning the stem cells that should become bone-forming osteoblasts instead become fat cells. Oxidative stress also promotes osteoclastogenesis, tipping the remodeling cycle further toward resorption. By neutralizing these reactive species, quercetin theoretically attacks the disease at one of its root causes rather than merely masking its symptoms.

To test that theory rigorously, the Chinese team conducted a systematic search of the Embase, MEDLINE, and Web of Science databases covering the literature up to March 2025, identifying comparative preclinical studies in which quercetin was administered to animal models of osteoporosis and compared against appropriate controls. The methodological rigor of each included trial was assessed using the SYRCLE risk of bias tool, a instrument specifically designed for laboratory animal research that evaluates domains such as sequence generation, allocation concealment, blinding, and selective outcome reporting. Statistical pooling was performed with Review Manager 5.4 software, with effects expressed as standardized mean differences, a metric that allows outcomes measured on different scales across different laboratories to be combined into a single coherent estimate. This is the essential work of meta-analysis: transforming a scattered literature of small, sometimes conflicting experiments into a quantitative statement about whether an effect is real.

The pooled results were consistently favorable to quercetin. Across the included trials, the compound improved bone tissue morphology as assessed by micro-computed tomography, the gold-standard imaging technique for quantifying three-dimensional bone microarchitecture in rodents. Key structural parameters, including bone volume fraction, trabecular thickness, and trabecular separation, all moved in the direction of healthier bone: more bone tissue, thicker structural struts, and wider spacing between trabeculae reversed. The meta-analysis also found that quercetin enhanced serum bone metabolism markers, the biochemical signals that reflect the ongoing tug-of-war between bone formation and bone resorption, and it increased bone mechanical strength, the ultimate functional endpoint that determines whether a bone will withstand the loads of daily life. In practical terms, animals treated with quercetin had bones that were structurally better built and mechanically more resilient than their untreated counterparts.

Perhaps the most actionable finding concerns dosage. The authors report that a potentially effective dose range in animal models falls between 100 and 150 milligrams per kilogram per day. This kind of dose-response information is invaluable for translating preclinical work toward clinical testing, because it gives future researchers a rational starting point for designing human trials rather than guessing at pharmacologically active levels. It is worth noting, however, that such doses in rodents are far higher than what any human could obtain from diet alone; a person eating a quercetin-rich diet typically consumes tens of milligrams per day, and even concentrated supplements deliver a small fraction of the normalized doses used in these animal experiments. Bioavailability is another persistent challenge, since quercetin is poorly absorbed and extensively metabolized in its native form, which is why some formulation strategies pair it with carrier molecules or use metabolites such as quercetin glycosides.

The mechanistic story that emerges from the review is a three-pronged one. First, quercetin’s antioxidative activity directly counters the reactive oxygen species that sabotage bone remodeling, protecting osteoblast precursors and reducing osteoclast activity, which the authors tracked in part through markers such as tartrate-resistant acid phosphatase, a classic enzymatic signature of bone-resorbing cells. Second, the compound promotes the osteogenic differentiation of bone marrow mesenchymal stem cells, nudging these multipotent cells toward becoming functional bone-forming osteoblasts, a process influenced by regulatory molecules including long non-coding RNAs that fine-tune gene expression during lineage commitment. Third, and perhaps most intriguingly for readers following the exploding field of gut-bone axis research, quercetin modulates the intestinal microbiota, increasing short-chain fatty acid production. Short-chain fatty acids are microbial metabolites with well-documented anti-inflammatory and bone-protective effects, and their elevation suggests that quercetin may act partly as a preclinical agent, reshaping the gut ecosystem in ways that ultimately benefit the skeleton.

The ovariectomized rodent, in which the ovaries are surgically removed to mimic the estrogen withdrawal of menopause, remains the workhorse model of postmenopausal osteoporosis, and it featured prominently in the included studies. While this model has proven its worth over decades of bone biology research, it is not a perfect proxy for human disease, and the authors are careful to frame their conclusions as evidence of a potential preventive effect rather than a demonstrated therapy. The SYRCLE assessment, though not detailed in full in the abstract-level reporting, serves as a reminder that laboratory animal studies are vulnerable to biases that can inflate apparent effects, and that small sample sizes, in this case 325 animals across fifteen trials, leave room for statistical uncertainty around the pooled estimates. Heterogeneity across studies, arising from differences in species, dose, route of administration, duration of treatment, and method of osteoporosis induction, is an inherent challenge in any meta-analysis of preclinical literature.

What makes this publication notable in the broader landscape is its timing and its method. Interest in flavonoids as nutraceutical interventions for chronic disease has surged, but the field has often been criticized for relying on isolated positive studies that fail to replicate. By applying the systematic review machinery, comprehensive database searches, formal risk-of-bias assessment, and quantitative pooling with confidence intervals, to a natural compound, the Zhejiang team has elevated the conversation from anecdote to evidence synthesis. The open-access publication, released on 6 October 2026 under a Creative Commons license, means that researchers anywhere in the world can scrutinize the data, the inclusion criteria, and the statistical methods, a transparency that is increasingly demanded of preclinical research given the field’s well-documented reproducibility problems.

The road from rodent bone to human prescription is long and littered with compounds that looked spectacular in animal models and failed in clinical trials. Quercetin will need to clear the same hurdles: pharmacokinetic studies establishing achievable human exposure, safety profiling at therapeutic doses, and ultimately randomized controlled trials measuring fracture outcomes, not just surrogate markers. Still, the convergence of evidence from this meta-analysis, antioxidant protection, stem cell fate redirection, and microbiome modulation, paints a coherent mechanistic picture that goes beyond a statistical association. For a compound that costs pennies and sits in the produce aisle, quercetin’s journey from kitchen staple to potential osteoporosis therapy is a story worth watching, and this rigorous synthesis provides the clearest quantitative map yet of where that journey stands today.

Subject of Research: Preclinical efficacy and mechanisms of quercetin in osteoporosis

Article Title: Therapeutic potential of quercetin in osteoporosis: a systematic review and meta-analysis of preclinical studies

Article References: Yan, Z., Liu, L., Su, H., Pan, Y., Chen, W., Zhu, K., Wu, M., Zhuang, R., & Guo, W. (2026). Therapeutic potential of quercetin in osteoporosis: a systematic review and meta-analysis of preclinical studies. BMC Complementary Medicine and Therapies. https://doi.org/10.1186/s12906-026-05593-y

Image Credits: AI Generated

DOI: 10.1186/s12906-026-05593-y

Keywords: quercetin, osteoporosis, meta-analysis, bone density, flavonoids, oxidative stress, bone marrow mesenchymal stem cells, gut microbiota, preclinical studies, bone metabolism, ovariectomy model, antioxidants

Exosomes belong to the broader family of extracellular vesicles, but they have a specific origin story that distinguishes them from other secreted particles. They form inside cells within compartments called multivesicular bodies, which are essentially endosomes studded with internal buds known as intraluminal vesicles. When these multivesicular bodies fuse with the cell’s outer membrane, the intraluminal vesicles are released into the surrounding fluid as exosomes. The process is orchestrated in large part by the endosomal sorting complexes required for transport, or ESCRT, a molecular machinery that decides which proteins are packed into each vesicle. Because the cargo is selected during biogenesis, exosomes are not random debris; they are curated snapshots of the physiological state of the cell that released them. That property is precisely what makes them so interesting to researchers studying tissues that communicate across anatomical boundaries.

The review’s first major theme is the pathway running from skeletal muscle to bone. Muscle-derived exosomes carry a payload rich in microRNAs, short RNA molecules that do not encode proteins but instead regulate gene expression by silencing target messenger RNAs. When muscle-derived exosomes are taken up by bone cells, these myogenic microRNAs can tip the balance of bone remodeling, the perpetual tug-of-war between osteoblasts, the cells that build bone, and osteoclasts, the cells that resorb it. According to the review, specific muscle-derived microRNAs and proteins influence the activity of both osteoblasts and osteoclasts, meaning that a healthy, contracting muscle can actively encourage bone formation while suppressing excessive breakdown. This provides a molecular explanation for a clinical observation that has long puzzled researchers: people who lose muscle mass almost invariably lose bone mass as well, and exercise that strengthens muscle tends to strengthen bone in parallel.

The reverse direction of the conversation is equally consequential. Bone is not a passive recipient of muscle-derived signals; it sends its own exosomal messages back. The review highlights exosomes derived from bone marrow mesenchymal stem cells, the regenerative cells resident in bone marrow, as particularly influential on muscle. These bone-derived vesicles affect myogenesis, the formation of new muscle fibers, and influence the process of muscle atrophy, the wasting that follows disuse, disease, or aging. In other words, the bone marrow appears to function as an endocrine-like organ in its own right, dispatching nanoscale couriers that help determine whether muscle tissue is maintained or lost. This bidirectional loop helps explain why osteosarcopenia behaves as a single coupled syndrome rather than two coincidental conditions, and why treating one tissue in isolation often fails to rescue the other.

Several specific molecular players illustrate how granular this communication can be. The review’s abbreviation list points to factors such as paired-related homeobox 2, a transcriptional regulator implicated in bone cell behavior, and lactate dehydrogenase A, a key enzyme of glycolytic metabolism, as components of the vesicular cargo that has drawn attention. Fluid flow shear stress, the mechanical stimulus that bone cells experience when interstitial fluid is pushed through the bone matrix during loading, also appears in the discussion, underscoring that mechanical forces and vesicular signals are intertwined rather than separate channels. Markers such as procollagen type I N-terminal propeptide and the beta-isomer of C-terminal telopeptide of type I collagen, standard clinical indicators of bone formation and resorption respectively, represent the kind of measurable endpoints that exosome research ultimately hopes to complement or refine. The chemokine receptor CXCR4, known for guiding stem cell migration and homing, hints at how vesicle-mediated signals might direct regenerative cells to where they are needed.

Beyond mechanism, the review devotes substantial attention to translation, and this is where the story becomes genuinely exciting for clinicians. Because exosomal cargo mirrors the state of the source tissue, circulating exosomes could serve as liquid biopsy markers for musculoskeletal health. A blood test that reads the molecular signatures of muscle-derived and bone-derived vesicles might one day detect the earliest shifts toward osteosarcopenia, long before a dual-energy X-ray scan registers meaningful loss of tissue. The review assesses this biomarker potential explicitly, positioning exosomes alongside established biochemical markers of bone turnover as a next generation of diagnostics. Early detection matters enormously in this field, because interventions that preserve muscle and bone are far more effective before irreversible structural damage has accumulated.

The therapeutic possibilities are equally striking. Exosomes are natural delivery vehicles: they are small, stable in circulation, protected by a lipid membrane, and capable of crossing biological barriers that defeat many synthetic drugs. Researchers are exploring two parallel strategies. The first uses naturally occurring exosomes, for example those secreted by mesenchymal stem cells, as ready-made therapeutics whose intrinsic cargo promotes regeneration. The second is engineering: loading exosomes with chosen microRNAs, proteins, or drugs and, ideally, decorating their surface with targeting molecules so that they home to muscle or bone specifically. The review also references work on exosomes from human fetal cartilage-derived progenitor cells, an example of how vesicles from unusual source tissues are being evaluated for regenerative applications. If either strategy matures, a single injectable product could theoretically stimulate osteoblasts, calm osteoclasts, and revive failing muscle fibers at once, addressing both faces of osteosarcopenia with one intervention.

The authors are careful, however, not to oversell the promise, and their discussion of limitations is one of the most valuable parts of the review. Isolation and characterization of exosomes remain inconsistent across laboratories, with different separation techniques yielding vesicle populations of varying purity and potency, which complicates comparisons between studies. Biodistribution is poorly understood: once injected, engineered or native exosomes may accumulate in the liver or spleen rather than reaching the intended tissue, and achieving reliable tissue-specific delivery is still an unsolved problem. Manufacturing at clinical scale under Good Manufacturing Practice conditions poses further hurdles, and the regulatory landscape is still taking shape. The review notes that exosome-based products would likely navigate frameworks developed for advanced therapy medicinal products in Europe and for Investigational New Drug and Biologics License Application pathways at the United States Food and Drug Administration, routes that demand rigorous control of identity, purity, and potency. Safety questions, including the possibility that vesicles could transfer harmful cargo or provoke immune reactions, remain open.

What emerges from the review is a picture of a field in rapid ascent but not yet at the clinic. The authors conclude that exosomes are critical mediators of muscle-bone crosstalk and that their cargo reflects the physiological state of the source cells, a foundation solid enough to justify serious investment in both diagnostics and therapeutics. They also argue that future progress will depend on integrating multi-omics approaches, which profile the full complement of RNAs, proteins, and metabolites in vesicle populations, with artificial intelligence tools capable of finding predictive patterns in those enormous datasets. Such combinations could identify which specific vesicle signatures predict fracture risk or muscle decline, and which cargo molecules are the true therapeutic effectors among thousands of passengers. For the millions of people facing osteosarcopenia, the prospect that the body’s own nanoscale messengers could be read like a lab report and reprogrammed like a drug is no longer science fiction; it is a research agenda with a clear roadmap, published as an open-access article that invites the global research community to build on it.

Subject of Research: Exosome-mediated molecular communication between skeletal muscle and bone and its therapeutic potential for osteosarcopenia

Article Title: Exosome-mediated muscle-bone crosstalk: mechanisms and therapeutic potential

Article References: Chen, D., Liu, J., Liang, X., Zhang, X., Bai, L., Qin, G., Min, T., Xiang, J., Li, K., & Xu, D. (2026). Exosome-mediated muscle-bone crosstalk: mechanisms and therapeutic potential. Journal of Translational Medicine. https://doi.org/10.1186/s12967-026-08994-2

Image Credits: AI Generated

DOI: 10.1186/s12967-026-08994-2

Keywords: exosomes, extracellular vesicles, muscle-bone crosstalk, osteosarcopenia, skeletal muscle, bone metabolism, osteoblasts, osteoclasts, microRNAs, bone marrow mesenchymal stem cells, biomarkers, drug delivery

The enzyme in question is protein arginine methyltransferase 6, or Prmt6, the only known writer of a histone mark called H3R2me2a—asymmetric dimethylation of arginine 2 on histone H3. This mark is generally associated with transcriptional repression and is mutually exclusive with the active H3K4 methylation marks, meaning that where H3R2me2a sits, genes tend to stay quiet. In cancer biology, Prmt6 has already earned a reputation as a brake on cellular senescence: by depositing H3R2me2a near genes such as p53 and p21, it suppresses the expression of senescence programmes and keeps cells proliferating. Whether the same anti-ageing mechanism operated in bone, however, had never been tested—until a team working under protocols approved by the Tongji University Committee for the Protection and Use of Laboratory Animals set out to interrogate it in mice.

The researchers built their case on two complementary models of osteoblast ageing. In the first, they exposed cultured newborn mouse skull-derived osteoblasts to 200 micromolar hydrogen peroxide for two hours, inducing oxidative-stress-driven senescence. In the second, they simply passaged the cells repeatedly, letting replicative exhaustion accumulate naturally. Both models worked as intended: western blots and quantitative PCR showed rising levels of the senescence markers P16 and P21, immunofluorescence confirmed their intracellular accumulation, and senescence-associated beta-galactosidase staining revealed a growing fraction of blue-stained, senescent cells. Crucially, as senescence deepened, Prmt6 and its H3R2me2a mark faded from the cells at both the mRNA and protein levels—the first hint that this epigenetic system weakens as osteoblasts age.

To test causality rather than mere correlation, the team isolated osteoblasts from Prmt6 knockout mice. Removing the enzyme crashed H3R2me2a levels, and the senescence programme surged: P16 and P21 climbed, beta-galactosidase-positive cells multiplied, and the expression of osteogenic markers—Alp, Ocn and the master transcription factor Runx2—fell significantly. In practical terms, bone-forming cells without Prmt6 not only looked old; they lost their ability to mature and mineralise matrix. Transcriptome-wide RNA sequencing reinforced the picture. Principal component analysis cleanly separated knockout cells from controls along the first principal component, and differential expression analysis identified 2,478 altered genes, 682 upregulated and 1,796 downregulated. Gene ontology and KEGG pathway enrichment pointed to a triad of disruption: suppressed ossification and collagen matrix assembly, enhanced immune cell migration and TNF-alpha production, and altered PI3K-Akt and Rap1 signalling pathways known to govern osteoblast survival and adhesion.

Among all these changes, one innate immune gene stood out. Cross-referencing the differentially expressed genes against Sting-pathway members yielded two candidates, Sting and Nfkbia, but only Sting was consistently and stably regulated by Prmt6 loss. Sting—the stimulator of interferon genes—is the central adaptor of the cGAS-STING pathway, which normally senses cytoplasmic DNA and launches a type I interferon response. In recent years, the pathway has been implicated in ageing far beyond its anti-infective origins: aberrant Sting activation drives chronic low-grade inflammation, senescence-associated secretory phenotype expression and, in the skeleton, mitochondrial dysfunction through the HK2-VDAC1 axis. In the knockout osteoblasts, Sting mRNA and protein rose sharply, and the same elevation appeared in both chemically induced and replicative senescence models.

The functional test followed: when the researchers knocked out Sting, senescence markers P16 and P21 dropped, the antioxidant enzyme Gpx4 increased, beta-galactosidase-positive cells declined, and the osteogenic markers Alp, Ocn and Runx2 rebounded. In other words, silencing Sting did not merely correlate with healthier osteoblasts—it partially rescued them from senescence and restored differentiation capacity. Sting, it appeared, was not an innocent bystander in the ageing bone but an active driver of the senescent state that Prmt6 loss had unleashed.

Downstream of Sting, the trail led to Ifitm3, an interferon-induced transmembrane protein better known for blocking enveloped viruses such as influenza and dengue by stiffening endosomal and lysosomal membranes. Ifitm3 is a classic interferon-stimulated gene, so when Sting signalling fires, Ifitm3 expression follows. The new data confirmed the dependency: Sting knockdown reduced Ifitm3 at every level measured. And like Sting, Ifitm3 climbed in senescent osteoblasts, in Prmt6-deficient cells, and in the femurs of naturally ageing mice, while Ifitm3 knockout reduced P16 and P21, lowered beta-galactosidase positivity, and boosted osteogenic gene expression. The authors suggest that by altering membrane fluidity, promoting lysosomal activity and disrupting autophagic flux, Ifitm3 may be one of the molecular hands that physically push an osteoblast into senescence—though they caution that the precise effector mechanisms remain to be disentangled.

The animal data tied the cellular story to real bone loss. Using micro-CT scanning at 25-micrometre resolution on femurs from mice aged 2, 12 and 24 months, the team documented the expected march of osteoporosis: trabecular number, bone volume fraction, bone surface density and trabecular thickness all fell with age, while trabecular separation widened. Haematoxylin and eosin staining showed coarsened trabecular edges, enlarged marrow spaces and microfractures. Superimposed on this structural decay was the molecular signature: Prmt6 and H3R2me2a declined progressively in femoral tissue, while Sting and Ifitm3 rose—mirroring exactly the gradients seen in the culture dish.

The authors are candid about the limits of the work. The chromatin accessibility changes at the Sting locus following H3R2me2a loss are currently correlative; direct causality, and the possibility that Prmt6 acts through H3R2me2a-independent routes, await rescue experiments. Likewise, whether Ifitm3 directly executes senescence or merely permits it remains unresolved, with experiments involving cholesterol-binding mutants, lysosomal pH modulators and live autophagic-flux monitoring now under way. Even so, the study assembles the first integrated link between a Prmt6-mediated histone modification, the Sting innate immune pathway and osteoblast senescence in vivo, and it reframes age-related osteoporosis as a disease in which the bone-forming compartment loses its epigenetic defences rather than one driven simply by overactive osteoclasts.

If the axis holds up, the therapeutic implications are considerable. The open chromatin state of the Sting locus could serve as a biomarker of osteoblast ageing, and drugs that restrain Sting signalling or restore H3R2me2a deposition might delay or partially reverse bone loss in the elderly. With population ageing intensifying worldwide and osteoporosis already a leading cause of disability and fracture-related mortality, an epigenetic handle on the disease would be a welcome addition to a therapeutic landscape dominated for decades by antiresorptive agents. The road from mouse femurs to human clinics is long, and the authors themselves flag that long-term efficacy and safety of any such epigenetic strategy must be systematically evaluated—but the mapping of this pathway marks a genuine step forward in understanding why our bones grow old.

Subject of Research: Epigenetic regulation of osteoblast senescence in age-related osteoporosis via the Prmt6/H3R2me2a/Sting/Ifitm3 pathway

Article Title: Prmt6 Deficiency Drives Osteoblast Senescence Promoting Age‐Related Osteoporosis via Epigenetic Remodelling of the H3R2me2a/Sting/Ifitm3 Pathway

Article References: Wang, Y., Ge, X., Chang, S., Wang, D., Xu, K., Xu, H., Liu, X., & Wang, S. (2026). Prmt6 Deficiency Drives Osteoblast Senescence Promoting Age‐Related Osteoporosis via Epigenetic Remodelling of the H3R2me2a /Sting/Ifitm3 Pathway. Journal of Cellular and Molecular Medicine, 30(18), Article e71308. https://doi.org/10.1111/jcmm.71308

Image Credits: AI Generated

DOI: 10.1111/jcmm.71308

Keywords: osteoporosis, osteoblast senescence, Prmt6, H3R2me2a, STING, Ifitm3, epigenetics, cellular ageing, bone metabolism, innate immunity, chromatin remodelling, ageing

Postmenopausal osteoporosis arises when declining estrogen levels tip the balance of bone remodeling toward resorption, producing reduced bone mass, deteriorated trabecular microstructure, and elevated fracture risk. As populations age worldwide, the disease imposes a growing public health burden on elderly women. Current first-line treatments, including bisphosphonates and hormone replacement therapy, effectively slow bone loss, but long-term use carries well-documented concerns ranging from gastrointestinal damage to cardiovascular risks and potential carcinogenic hazards. That trade-off has driven researchers to search for natural compounds with genuine anti-osteoporotic activity and favorable safety profiles.

The research team, led by Zhaoguo Wang of Southern Medical University, turned to Auricularia auricula, an edible medicinal fungus whose polysaccharides have previously shown antioxidant, anti-inflammatory, and gut-regulating properties. To maximize yield, the group developed an ultrasound-assisted enzymatic extraction method, first screening cellulase, pectinase, and a combination of the two. The enzyme cocktail proved decisively superior, lifting the extraction yield to 27.72 percent compared with 24.02 percent for cellulase alone and 15.23 percent for pectinase alone, a synergy attributed to the enzymes attacking different structural components of the fungal cell wall simultaneously.

With the enzyme system selected, the researchers systematically optimized each extraction variable. Single-factor experiments identified a cellulase-to-pectinase ratio of 1.5:1, an enzyme concentration of 3000 units per 100 milliliters, a four-hour enzymolysis, a 1:40 solid-to-liquid ratio, twenty minutes of sonication, and an ultrasonic power of 2 watts per milliliter as favorable conditions. A Box-Behnken response surface design then refined four key parameters into a predictive model with strong explanatory power, achieving a coefficient of determination of 0.9156 and a non-significant lack-of-fit test. Validation runs under practical near-optimal conditions delivered an experimental yield of 30.15 percent, within 2.87 percent of the model prediction and inside the 95 percent prediction interval, confirming the reliability of the optimized process.

Characterization revealed that the resulting Auricularia auricula polysaccharide, or AAP, is an acidic heteropolysaccharide rich in glucose, mannose, and glucuronic acid, with smaller contributions from fucose and xylose. Total sugar content reached 74.07 percent, uronic acid 10.37 percent, and protein only 2.63 percent, while endotoxin levels remained low across the tested concentration range. Infrared spectroscopy identified hallmark polysaccharide absorptions, including hydroxyl stretching near 3000 to 3500 inverse centimeters, a carbonyl band consistent with glucuronic acid carboxyl groups, and a signal at 848 inverse centimeters indicating beta-configured sugar units. Molecular weight analysis showed a heterogeneous mixture spanning roughly one thousand to one and a half million Daltons, and thermal analysis demonstrated stability up to approximately 270 degrees Celsius, well above physiological temperatures.

The structural profile matters because polysaccharide bioactivity is thought to depend heavily on molecular weight and monosaccharide composition. Acidic, uronic-acid-rich polysaccharides cannot cross cell membranes, but their negatively charged carboxyl groups can engage positively charged receptor domains through electrostatic attraction. Notably, the extracellular domain of the insulin-like growth factor 1 receptor is enriched in arginine and lysine residues, making it a plausible anchoring target for anionic polysaccharides. This structural logic shaped the team’s central hypothesis: that AAP might stimulate osteoblasts not through the canonical BMP/Smad or Wnt/beta-catenin routes used by neutral fungal glucans, but through the IGF-1/IGF-1R signaling axis.

To test the hypothesis in living animals, the researchers used an ovariectomized rat model, the standard experimental surrogate for postmenopausal bone loss. Female rats underwent bilateral ovariectomy and, after a week of recovery, received daily oral AAP at 100, 300, or 500 milligrams per kilogram for twelve weeks, alongside sham, ovariectomy-only, and estradiol-treated control groups. Micro-computed tomography of the proximal tibia showed that only the high dose significantly increased bone mineral density and improved trabecular microarchitecture relative to untreated ovariectomized animals. Histological staining corroborated the imaging: high-dose AAP increased the bone area fraction and reduced the osteoclast-covered bone surface, mirroring the effects of estradiol without stimulating uterine tissue, a key safety distinction for any non-hormonal therapy.

Serum biomarkers told a consistent story. Ovariectomized rats displayed elevated CTX-1 and RANKL, markers of rampant bone resorption, alongside depressed P1NP, OPG, and the protective OPG-to-RANKL ratio. High-dose AAP reversed all of these shifts and restored serum IGF-1, which had fallen sharply after ovariectomy. Because IGF-1 is the most abundant growth factor stored in bone matrix and a well-established driver of osteoblast differentiation, proliferation, and survival, its recovery pointed directly toward the signaling axis the team suspected. Importantly, no abnormalities appeared in major organ indices or histology across the treatment groups, and AAP did not raise the uterine index at any dose tested.

In vitro experiments then dissected the mechanism at cellular resolution. AAP did not alter the proliferation of bone marrow stromal cells or MC3T3-E1 pre-osteoblasts, but the high concentration markedly enhanced osteogenic differentiation, boosting alkaline phosphatase activity at day seven and matrix mineralization at day twenty-one. Western blotting revealed increased IGF-1 and IGF-1R protein levels, elevated phosphorylation of IGF-1R, IRS-1, AKT, and ERK, and upregulation of core osteogenic genes including RUNX2, ALP, COL-1, OSX, and OPG. Total protein levels of Smad2, Smad3, Wnt4, and beta-catenin were unchanged, though the authors caution that this alone cannot exclude activation of those pathways. The decisive experiment came with CRISPR/Cas9-generated IGF-1R knockout cells: in these, the AAP-driven gains in alkaline phosphatase activity, mineralization, and osteogenic gene expression were largely abolished, providing functional proof that the receptor is required for the full effect.

The team also addressed a question critical to any functional food: does the compound survive digestion? Simulated oral, gastric, and intestinal digestion phases left AAP’s osteogenic activity essentially intact, with all digested fractions sustaining elevated alkaline phosphatase activity in human osteoblasts indistinguishable from the undigested compound. The authors acknowledge limitations, including the imperfect fidelity of the ovariectomy model to human disease and the absence of formal pharmacokinetic and long-term toxicity studies, though pharmacokinetic data from a structurally analogous Auricularia polysaccharide suggest efficient oral absorption. Further work to purify individual molecular weight fractions, map upstream receptor interactions, and complete safety profiling will determine whether this kitchen-staple fungus can move from the wok to the clinic as a bone-protective functional food.

Subject of Research: Osteoprotective effects and IGF-1/IGF-1R mechanism of Auricularia auricula polysaccharides in postmenopausal osteoporosis

Article Title: Preparation and physicochemical characterization of polysaccharides from Auricularia auricula and their osteogenic potential in vitro and in vivo

Article References: Wang, Z., Liu, G., Lai, F., Xiao, X., & Xu, S. (2026). Preparation and physicochemical characterization of polysaccharides from Auricularia auricula and their osteogenic potential in vitro and in vivo. Journal of Agriculture and Food Research, 31, Article 103263. https://doi.org/10.1016/j.jafr.2026.103263

Image Credits: AI Generated

DOI: 10.1016/j.jafr.2026.103263

Keywords: Auricularia auricula, wood ear mushroom, polysaccharides, postmenopausal osteoporosis, osteogenic differentiation, IGF-1/IGF-1R signaling, bone mineral density, ovariectomized rats, ultrasound-assisted enzymatic extraction, functional food, bone metabolism, natural products

The clinical backdrop to the work is well established. Epidemiological studies have repeatedly shown that patients with Parkinson’s disease face a strikingly elevated risk of osteoporosis and osteoporotic fractures, a burden that exceeds what can be explained by poor mobility, falls, or age alone. Meta-analyses cited by the researchers indicate high rates of osteoporotic fracture in Parkinson’s disease, and cross-sectional clinical work has associated biomarkers such as serum uric acid with reduced bone mineral density in affected patients. Yet the molecular mechanisms that bind neurodegeneration to bone loss have remained murky. The Henan University team set out to interrogate that relationship experimentally, asking whether a single genetic factor—absence of ACE2—could simultaneously perturb dopaminergic neuron survival in the brain and bone homeostasis in the skeleton.

To do so, the researchers used a well-characterized mouse model of parkinsonism in which the neurotoxin MPTP, or 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, selectively destroys dopamine-producing neurons in the substantia nigra. Crucially, they crossed this challenge with mice lacking a functional ACE2 gene—specifically Ace2-null males, designated Ace2−/y—because ACE2 sits at the center of the protective arm of the renin-angiotensin system, converting angiotensin II into angiotensin-(1–7), a peptide with documented anti-inflammatory and neuroprotective actions. Previous studies from other groups and from the same team had shown that ACE2 activation mitigates behavioral deficits and neuroinflammation in chemically induced Parkinson’s models, and that the ACE2/Ang-(1–7)/Mas cascade strengthens bone structure and metabolism. The new study asked what happens when this protective factor is removed entirely under parkinsonian stress.

Behavioral testing revealed a clear aggravating effect. MPTP exposure significantly worsened motor dysfunction and depression-like behaviors in the mice, and the combination of MPTP toxicity with ACE2 deficiency produced a particularly severe pathological picture in the brain. Immunohistochemistry, Western blotting, and histopathological staining showed reduced activity of dopaminergic neurons and heightened microglial activation—the inflammatory response of the brain’s resident immune cells. At the molecular level, the researchers measured elevated levels of total α-synuclein, the misfolding-prone protein that defines Parkinson’s pathology, alongside increased abundance of Caspase-3 and Bax, two canonical executioners of programmed cell death. Together, these markers indicate that ACE2 loss intensifies both the protein aggregation burden and the apoptotic pressure on vulnerable neurons.

The bone findings were equally striking, and notably they emerged in parallel rather than secondarily. In the skeletal tissue of the Ace2-deficient mice, the team documented reduced abundance of total Wnt ligands, β-catenin, bone morphogenetic proteins (BMP), and insulin-like growth factor 1 (IGF-1), along with diminished phosphorylation ratios of the downstream kinases that transmit these signals. This matters because each of these cascades is a cornerstone of bone formation: Wnt/β-catenin signaling drives osteoblast differentiation and bone accrual, BMPs are potent inducers of bone formation used clinically in spine fusion and fracture repair, and IGF-1 couples muscle and bone metabolism through mTOR-dependent pathways. The researchers are careful to note that the parallel reduction of these signaling proteins suggests potential perturbation of the cascades rather than definitive proof of pathway failure, a distinction that reflects appropriate scientific caution.

In the opposite direction, ACE2 deficiency upregulated mediators of the RANKL/RANK/OPG axis, a triad that governs osteoclast formation and bone resorption. RANKL binding to RANK on osteoclast precursors drives the differentiation of bone-resorbing cells, while OPG acts as a soluble decoy receptor that restrains the process. Dysregulation of this axis tilts bone turnover toward net loss. Intriguingly, the same axis operates in the brain, where it has been identified as a critical inflammatory signaling system in ischemic injury, and Rho GTPases downstream of these pathways modulate osteoclast differentiation directly. The coordinated shift of this inflammatory skeletal axis in both brain and bone tissue under ACE2 deficiency is one of the study’s most suggestive observations, hinting at a common pathological language spoken by the two organs.

To move from candidate pathways to gene-level targets, the team turned to transcriptomics. They mined public GEO datasets and applied weighted gene co-expression network analysis, or WGCNA, a computational method that groups genes into modules based on correlated expression patterns and identifies the hub genes most central to disease-associated modules. This analysis pinpointed ten hub genes, including DNM1, which encodes dynamin 1, a protein essential for synaptic vesicle recycling; OCRL, a phosphatidylinositol phosphate phosphatase linked to the oculocerebrorenal syndrome; and OPA1, a mitochondrial fusion protein whose mutations cause dominant optic atrophy and which has been implicated in mitochondrial parkinsonism through stem cell modeling. The dysregulation of these genes was linked to synaptic dysfunction and inflammation—two processes squarely at the heart of Parkinson’s pathophysiology.

The team then evaluated whether these hub genes could serve as diagnostic biomarkers. Using receiver operating characteristic, or ROC, analysis on public single-disease transcriptome datasets for Parkinson’s disease and osteoporosis separately, they found that the core gene signatures achieved areas under the curve ranging from 0.683 to 0.981, indicating diagnostic accuracy that spans moderate to near-perfect discrimination. Functional enrichment of the core genes pointed to involvement in synaptic signaling, MAPK signaling, and the Rap1 and Ras pathways—small GTPase cascades that regulate cell proliferation, differentiation, and cytoskeletal dynamics in both neurons and bone cells. Such dual-diagnostic performance, if replicated in human cohorts, would suggest that a shared molecular signature underlies both conditions and could be exploited clinically to identify patients at risk of combined neurodegenerative and skeletal decline.

The authors are appropriately measured in their claims. They emphasize that these are preclinical findings obtained under short-term MPTP treatment in growing young male mice, meaning that the observed bone metabolic disturbance was transient and that the results may not translate directly to elderly human patients, in whom Parkinson’s disease typically manifests and in whom bone loss is chronic and sex-dependent. They also stress that the coordinated dysregulation observed in brain and bone is consistent with a bone-brain axis pathological phenotype, but that the current experimental design cannot confirm causal bidirectional cross-talk between the tissues. Distinguishing whether ACE2 deficiency independently damages both organs, or whether pathology in one propagates to the other—perhaps through circulating osteocalcin, sympathetic nervous system output, or inflammatory mediators—will require interventional studies that manipulate one tissue and measure the other.

Even with those caveats, the study offers a compelling framework and a set of concrete targets for follow-up. Restoring ACE2 activity or mimicking its product, angiotensin-(1–7), has already shown neuroprotective effects in experimental Parkinson’s models, including reduced α-synuclein expression through the NEAT1/miR-153-3p axis, and ACE2 activation has been reported to promote hippocampal neurogenesis via Wnt/β-catenin signaling. The present results raise the possibility that such therapies could carry a skeletal benefit as well, protecting against the osteoporosis that so often compounds the disability of Parkinson’s disease. The ten hub genes, meanwhile, provide a molecular shortlist for mechanistic validation, and their diagnostic AUC values justify testing in human blood or tissue datasets. As the bone-brain axis matures from a descriptive concept into a mechanistic research program, work like this demonstrates how a single molecule, studied across two organs at once, can illuminate disease connections that medicine has long observed clinically but struggled to explain at the level of genes and signaling pathways.

Subject of Research: ACE2-dependent molecular mechanisms linking Parkinson's disease neurodegeneration and bone metabolic alterations via the bone-brain axis

Article Title: ACE2 and Parkinsonism‑related bone metabolic alterations: signaling pathways and hub gene analysis

Article References: Liu, T., Ren, Y., Tian, X., & Wei, J. (2026). ACE2 and Parkinsonism‑related bone metabolic alterations: signaling pathways and hub gene analysis. Molecular Genetics and Genomics, 301(1), Article 185. https://doi.org/10.1007/s00438-026-02511-2

Image Credits: AI Generated

DOI: 10.1007/s00438-026-02511-2

Keywords: Parkinson's disease, ACE2, bone metabolism, bone-brain axis, osteoporosis, Wnt/beta-catenin signaling, RANKL/RANK/OPG, IGF-1, hub genes, WGCNA, alpha-synuclein, MPTP mouse model

The scale of the problem they targeted is enormous. More than nine million osteoporotic fractures occur worldwide each year, and people living with diabetes mellitus face a 20 to 50 percent higher risk of fragility fractures than the general population. Diabetic osteoporosis is increasingly described as a dual pandemic, driven by mechanisms that differ fundamentally from ordinary age-related bone loss. Advanced glycation end products, insulin resistance, oxidative stress, and elevated inflammatory cytokines all conspire to disrupt bone metabolism, lowering osteoprotegerin while raising RANKL, a signal that fuels osteoclast-driven bone resorption. At the same time, chronic inflammation and hyperglycemia push bone-forming osteoblasts toward apoptosis and steer mesenchymal stem cells away from bone formation and toward fat production, a molecular switch governed by activated PPAR-gamma and suppressed Runx-2 expression.

Because existing antidiabetic drugs manage blood glucose imperfectly and carry side effects without curing the underlying disease, the research team turned to bioinformatics to hunt for multi-target natural molecules. Their strategy began with predicting genistein’s pharmacokinetic profile using the SwissADME web tool and its oral toxicity using ProTox-II and ProTox-3.0, which returned encouraging drug-likeness scores and low predicted toxicity. They then mined the GeneCards and Comparative Toxicogenomic databases for disease targets, retrieving a staggering 32,133 genes associated with diabetes mellitus and osteoporosis, and used Swiss Target Prediction to identify 105 human protein targets for genistein itself.

Overlaying the two gene sets produced a protein-protein interaction network of 104 nodes and 606 edges, visualized in Cytoscape and analyzed through topological parameters including degree, betweenness centrality, and closeness centrality. Five hub genes rose decisively above the rest: EGFR, the epidermal growth factor receptor; ESR1, the estrogen receptor alpha; MMP9, matrix metalloproteinase-9; PTGS2, the inflammatory cyclooxygenase-2 enzyme; and PPARG, the nuclear receptor governing fat and glucose metabolism. Gene ontology and KEGG pathway enrichment analyses revealed that these targets converge on the PPAR signaling pathway and EGFR tyrosine kinase inhibitor resistance pathways, alongside biological processes spanning apoptosis regulation, stress response, growth factor signaling, and catecholamine metabolism.

The computational deep-dive then moved to the atomic scale. Molecular docking using Schrödinger’s Glide module showed genistein binding strongly to all four top targets, with the strongest standard-precision score of minus 10.752 kcal/mol against ESR1, followed by minus 8.381 against EGFR, minus 7.096 against MMP9, and minus 6.495 against PPARG. Each complex was anchored by specific hydrogen bonds and hydrophobic contacts within the binding pockets, indicating that the soy isoflavone nestles into the same active regions as purpose-built synthetic drugs.

Docking, however, captures only a frozen snapshot. To test whether these interactions survive the thermal chaos of a living cell, the team ran 100-nanosecond molecular dynamics simulations in triplicate for each protein-ligand complex using the Desmond engine at 300 Kelvin under constant pressure and temperature. All four systems equilibrated within 20 nanoseconds and remained stable throughout. Backbone root-mean-square deviations stayed between 1.8 and 2.5 angstroms, ligand RMSD values remained below 2 angstroms, and active-site residues fluctuated less than 1.5 angstroms. The ESR1 and PPARG complexes proved especially robust, maintaining three to four hydrogen bonds for roughly 80 to 88 percent of the trajectory and retaining high alpha-helical content of about 55 to 57 percent, signatures of thermodynamically stable, persistent binding.

MM/GBSA free energy calculations sealed the computational case. The ESR1 complex posted the most favorable binding free energy at minus 51.86 kcal/mol, followed by EGFR at minus 49.23 and PPARG at minus 42.82, with van der Waals, electrostatic, and nonpolar solvation terms driving the favorable energetics. These numbers confirmed that genistein’s grip on its targets is not an artifact of rigid-receptor scoring but a genuinely stable molecular partnership sustained by the same forces that govern real drug binding.

Crucially, the researchers did not stop at the computer. In a dexamethasone-induced insulin resistance rat model, a well-established experimental mimic of type 2 diabetes metabolic dysfunction, genistein was formulated as a solid dispersion with PVP-K30 to improve solubility and administered orally at 1, 2, and 4 mg/kg daily for 25 days. Post-treatment, genistein-treated rats showed statistically significant reductions in fasting blood glucose and serum insulin compared with untreated positive controls, with the highest dose performing best, indicating restored insulin sensitivity.

The skeletal results were equally compelling. Scanning electron microscopy of rat femurs revealed that diabetic control animals had porous, microcracked, eroded trabecular surfaces and visible resorption pits, while genistein-treated bones appeared dense, compact, and structurally organized. Nanoindentation showed that treated animals maintained tissue-level hardness and reduced modulus close to normal values, and three-point bending tests demonstrated dramatic mechanical recovery: maximum load capacity in the highest-dose group reached 67.4 newtons, exceeding even the normal control value of 60.81 newtons, while the untreated diabetic group collapsed to just 10.33 newtons. Ultimate stress, stiffness, and toughness all followed the same restorative pattern.

Mechanistically, the findings weave a coherent story. EGFR dysregulation impairs the PI3K/AKT insulin signaling axis and undermines osteoblast survival, while genistein’s selective affinity for estrogen receptor beta and modulation of NF-kB and MAPK pathways counteracts inflammation-driven bone resorption. MMP9, overexpressed under hyperglycemic oxidative stress, chews through bone matrix and is partially responsible for skeletal degradation in diabetic animals, and PPAR-gamma overactivation diverts bone marrow stem cells into fat rather than bone. By binding all of these targets simultaneously, genistein appears to act as a dual-action agent, lowering blood glucose while defending bone microarchitecture and mechanical strength. The authors caution that further clinical and translational work is needed, but their integrated evidence positions this inexpensive soy-derived phytoestrogen as a promising template for evidence-based functional foods and tailored therapeutics against a complication that diabetes medicine has long undermanaged.

Subject of Research: Genistein as a multi-target phytoestrogen therapy for diabetic osteoporosis, investigated through network pharmacology, molecular docking, molecular dynamics simulation, and rat model experiments

Article Title: Genistein potential and mechanisms against diabetes osteoporosis: An integrated study of network pharmacology, molecular docking, and molecular dynamics simulation

Article References: Sharma, S., Chaudhary, R., Hooda, T., Sharma, C., Dabral, S., Kumar, A., Bansal, S., & Gupta, S. (2026). Genistein potential and mechanisms against diabetes osteoporosis: An integrated study of network pharmacology, molecular docking, and molecular dynamics simulation. Results in Chemistry, 30, Article 103833. https://doi.org/10.1016/j.rechem.2026.103833

Image Credits: AI Generated

DOI: 10.1016/j.rechem.2026.103833

Keywords: genistein, diabetic osteoporosis, network pharmacology, molecular docking, molecular dynamics simulation, MM/GBSA, EGFR, ESR1, MMP9, PPARG, insulin resistance, bone metabolism